enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. US FDA approves Amgen drug for small cell lung cancer - AOL

   www.aol.com/news/us-fda-approves-amgen-drug...

   The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen's tarlatamab, a targeted immunotherapy for adults in the advanced stages of hard-to-treat small cell lung ...

3. PD-1 and PD-L1 inhibitors - Wikipedia

   en.wikipedia.org/wiki/PD-1_and_PD-L1_inhibitors

   It was later approved for metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. In 2017, it became the first immunotherapy drug approved for use based on the genetic mutations of the tumor rather than the site of the tumor.

4. Cancer immunotherapy - Wikipedia

   en.wikipedia.org/wiki/Cancer_immunotherapy

   Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving the immune system's natural ability to fight the disease. [1] It is an application of the fundamental research of cancer immunology (immuno-oncology) and a growing subspecialty of oncology.

5. Checkpoint inhibitor - Wikipedia

   en.wikipedia.org/wiki/Checkpoint_inhibitor

   It was approved in 2014. Nivolumab is approved to treat melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancer, and Hodgkin's lymphoma. [16] Pembrolizumab (brand name Keytruda) is another PD-1 inhibitor that was approved by the FDA in 2014 and was the second checkpoint inhibitor approved in the United States. [17]

6. This Lung Cancer Drug Could Let Patients Forgo Chemo ... - AOL

   www.aol.com/news/lung-cancer-drug-could-let...

   This Lung Cancer Drug Could Let Patients Forgo Chemo—And It's Sending Merck's Stock Soaring. Skip to main content. Sign in. Mail. 24/7 Help. For premium support please call: 800-290-4726 more ...

7. Treatment of lung cancer - Wikipedia

   en.wikipedia.org/wiki/Treatment_of_lung_cancer

   Chemotherapy for NSCLC usually includes combination of two drugs (chemotherapy doublet), with one of the agents is cisplatin or carboplatin. In 2002, Schiller at al. published in the New England Journal of Medicine, a study that compared four chemotherapy regimens for advanced NSCLC, cisplatin and paclitaxel, cisplatin and gemcitabine, cisplatin and docetaxel, and carboplatin and paclitaxel. [14]